TABLE 3.
Drug | Res | Sus | Gene | Prem. stop codons in res. strains | Prem. stop codons in sus. strains | p-value |
RMP | 771 | 2710 | rpoC | 3 | 1 | 0.011 |
rpoB | 2 | 0 | 0.008∗ | |||
inhA | 1 | 0 | 0.137 | |||
INH | 1093 | 2420 | kasA | 3 | 0 | 0.01∗ |
ahpC | 1 | 2 | 0.934 | |||
katG | 13 | 0 | < 1.0e−5∗ | |||
STM | 728 | 1239 | rpsL | 1 | 0 | 0.192 |
gidB | 42 | 40 | 0.006∗ | |||
embA | 1 | 4 | 0.658 | |||
embR | 3 | 4 | 0.021 | |||
EMB | 466 | 3040 | embC | 1 | 4 | 0.658 |
embB | 1 | 2 | 0.306 | |||
ubiA | 1 | 0 | 0.011 | |||
PZA | 325 | 2993 | pncA | 372 | 7 | < 1.0e−5∗ |
panD | 6 | 0.148 | ||||
ETH | 49 | 175 | inhA | 1 | 0 | 0.058 |
ethA | 21 | 24 | < 1.0e−5∗ | |||
CAP | 116 | 1024 | tlyA | 2 | 2 | 0.008∗ |
Genes annotated with premature stop codons in the mutation library are shown in bold. It was tested whether genes with premature stop codons were equally distributed between the two phenotypic groups. This was tested using a χ2 test on a 2 × 2 matrix, and the p-value is given. ∗p-value below the significance level 0.01. Res, population of resistant strains; Sus, population of susceptible strains. RMP, Rifampicin; INH, Isoniazid; STM, Streptomycin; EMB, Ethambutol; PZA, Pyrazinamide; ETH, Ethionamide; CAP, Capreomycin.